Nirogacestat in Patients With Kaposi Sarcoma

This phase II trial studies how well nirogacestat works in treating patients with skin Kaposi sarcoma (KS). Several anti-cancer drugs work well in treating KS, but there is no treatment that cures KS. Nirogacestat binds to a protein called gamma secretase, which blocks the activation of other proteins called Notch receptors. Blocking these proteins may help keep tumor cells from growing and may kill them. Nirogacestat is a type of gamma secretase inhibitor. Nirogacestat may be effective in shrinking the size of KS lesions and reducing the spread of lesions.

Trial Details

NCT ID
NCT07539454
Phase
PHASE2
Sponsor
AIDS Malignancy Consortium
Status
RECRUITING
Cancer Type
Sarcoma
Interventions
  • Biospecimen Collection
  • Chest Radiography
  • Computed Tomography
  • Nirogacestat
  • Skin Biopsy
Locations (sample)
  • St Louis, Missouri, United States|38.62727,-90.19789

Key Eligibility Criteria

  • Biopsy-proven KS involving skin with or without visceral involvement either newly diagnosed or refractory to or intolerant of one or more prior the…
  • Patients must have cutaneous lesion(s) amenable to six total biopsies (minimum size of biopsy to be 4 mm), either six lesions \> 4 mm or one large …
  • Hemoglobin ≥ 8 g/dL (within three months prior to study entry)
  • Absolute neutrophil count (ANC) ≥ 1,000 cells/mm\^3 (within three months prior to study entry)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Sarcoma Trials on Trialify →